139 related articles for article (PubMed ID: 22258711)
1. Choline PET/CT compared with bone scintigraphy in the detection of bone metastases in prostate cancer patients.
Beheshti M; Langsteger W
Eur J Nucl Med Mol Imaging; 2012 May; 39(5):910-1; author reply 912-3. PubMed ID: 22258711
[No Abstract] [Full Text] [Related]
2. [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy.
Picchio M; Spinapolice EG; Fallanca F; Crivellaro C; Giovacchini G; Gianolli L; Messa C
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):13-26. PubMed ID: 21932120
[TBL] [Abstract][Full Text] [Related]
3. Bone metastases from prostate cancer: 18F-fluoride PET/CT in a patient with discordant bone scintigraphy and 11C-choline PET/CT.
Garcia G; Riera E; Valls E; Soler M; Bassa P; Moragas M; Lomeña F
Clin Nucl Med; 2013 Feb; 38(2):120-4. PubMed ID: 23334127
[TBL] [Abstract][Full Text] [Related]
4. Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy.
Fuccio C; Castellucci P; Schiavina R; Guidalotti PL; Gavaruzzi G; Montini GC; Nanni C; Marzola MC; Rubello D; Fanti S
Eur J Radiol; 2012 Aug; 81(8):e893-6. PubMed ID: 22621862
[TBL] [Abstract][Full Text] [Related]
5. A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer.
Wondergem M; van der Zant FM; van der Ploeg T; Knol RJ
Nucl Med Commun; 2013 Oct; 34(10):935-45. PubMed ID: 23903557
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Intramedullary Reactive Fibrosis as Mimic of Prostate Cancer Bone Metastasis on 11C-Choline Positron Emission and Computed Tomography.
Trump T; Luchey AM; Hogg J; Mattes MD
Pract Radiat Oncol; 2019 Jan; 9(1):e1-e3. PubMed ID: 30611465
[No Abstract] [Full Text] [Related]
8. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
9. [18F]fluorocholine PET/CT in the assessment of bone metastases in prostate cancer.
Beheshti M; Vali R; Langsteger W
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1316-7; author reply 1318-9. PubMed ID: 17476505
[No Abstract] [Full Text] [Related]
10. Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer.
Zattoni F; Agostini E; Cattaneo F; Maruzzo M; Basso U; Zattoni F; Evangelista L
Clin Imaging; 2017; 43():110-116. PubMed ID: 28278446
[TBL] [Abstract][Full Text] [Related]
11. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.
Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
BJU Int; 2012 Nov; 110(10):1501-6. PubMed ID: 22502982
[TBL] [Abstract][Full Text] [Related]
12. [Metabolic and osteogenic pattern of prostate cancer bone metastases].
García JR; Riera E; Valls E; Soler M; Moragas M; Lomeña F
Rev Esp Med Nucl Imagen Mol; 2013 Jan; 32(1):33-6. PubMed ID: 22835661
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostic relevance of choline-PET / CT in patients with prostate cancer].
Zengerling F; Schrader AJ; Schrader M; Jentzmik F
Aktuelle Urol; 2012 Jan; 43(1):49-54. PubMed ID: 21769763
[TBL] [Abstract][Full Text] [Related]
14. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W
Mol Imaging Biol; 2010; 12(1):98-107. PubMed ID: 19588206
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
16. The role of 18F-flourocholine PET/CT in biochemically relapsed prostate cancer: a case of osteolytic prostate metastasis.
Tabrizipour AI; Dunne M
Clin Nucl Med; 2015 May; 40(5):e285-6. PubMed ID: 25608148
[TBL] [Abstract][Full Text] [Related]
17. 11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer.
Ceci F; Castellucci P; Graziani T; Schiavina R; Chondrogiannis S; Bonfiglioli R; Costa S; Virgolini IJ; Rubello D; Fanti S; Colletti PM
Clin Nucl Med; 2015 May; 40(5):e265-70. PubMed ID: 25783519
[TBL] [Abstract][Full Text] [Related]
18. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W
Mol Imaging Biol; 2009; 11(6):446-54. PubMed ID: 19326171
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET/CT superscan in prostate cancer.
Bailly M; Besse H; Kerdraon R; Metrard G; Gauvain S
Clin Nucl Med; 2014 Oct; 39(10):912-4. PubMed ID: 24566401
[TBL] [Abstract][Full Text] [Related]
20. Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis.
Zhou J; Gou Z; Wu R; Yuan Y; Yu G; Zhao Y
Skeletal Radiol; 2019 Dec; 48(12):1915-1924. PubMed ID: 31127357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
